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1 Ecole Nationale Vétérinaire de Toulouse, Institut National de la Recherche Agronomique, TOXALIM, Université de Toulouse,
Toulouse, France, 2 Comparative Biomedical Sciences, The Royal Veterinary College, Hatfield, UK
Given that: (1) the worldwide consumption of antimicrobial drugs (AMDs) used in food-
producing animals will increase over the coming decades; (2) the prudent use of AMDs
will not suffice to stem the rise in human antimicrobial resistance (AMR) of animal
origin; (3) alternatives to AMD use are not available or not implementable, there is an
urgent need to develop novel AMDs for food-producing animals. This is not for animal
health reasons, but to break the link between human and animal resistomes. In this
review we establish the feasibility of developing for veterinary medicine new AMDs,
termed “green antibiotics,” having minimal ecological impact on the animal commensal
and environmental microbiomes. We first explain why animal and human commensal
microbiota comprise a “turnstile” exchange, between the human and animal resistomes.
We then outline the ideal physico-chemical, pharmacokinetic, and pharmacodynamic
properties of a veterinary green antibiotic and conclude that they can be developed
through a rational screening of currently used AMD classes. The ideal drug will be
hydrophilic, of relatively low potency, slow clearance and small volume of distribution.
It should be eliminated principally by the kidney as inactive metabolite(s). For oral
administration, bioavailability can be enhanced by developing lipophilic pro-drugs. For
parenteral administration, slow-release formulations of existing eco-friendly AMDs with a
short elimination half-life can be developed. These new eco-friendly veterinary AMDs can
be developed from currently used drug classes to provide alternative agents to those
currently used in veterinary medicine and mitigate animal contributions to the human
AMR problem.
Keywords: innovative eco-friendly antimicrobials, veterinary medicine, public health, commensal microbiota,
environmental hazard
INTRODUCTION
The links between animals and humans, in respect of the emergence and spread of resistance, is
a major global issue. This review proposes the development for veterinary medicine of new and
innovative drugs for food-producing animals; this is not for animal health reasons but rather to
mitigate the veterinary contribution to the human resistome.
Abbreviations: AMD, antimicrobial drugs; AMR, antimicrobial resistance; AUC, area under the curve; CVMP, Committee
for Medicinal Products for Veterinary Use; EMA, European Medicine Agency; GIT, gastro intestinal tract; MIC, minimum
inhibitory concentration; MW, molecular weight; PK/PD, pharmacokinetic/pharmacodynamic.
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Currently, food-producing animal medicine does not face
the same critical situation as human medicine, because there
are neither life-threatening infections of multiply drug resistant
microorganisms causing sepsis nor chronic conditions in poultry,
pigs, or cattle for which AMD therapy is mandatory. In addition,
the prevalence of resistance for major veterinary pathogens that
cannot be treated by any AMD is very limited. However, this
review proposes a renewal of the veterinary armamentarium
with drugs designed to break, for public health reasons, the
link between human and veterinary medicine. We have termed,
these innovative compounds “green antibiotics,” as they will have
minimal (ideally no) ecological impact on the animal commensal
microbiome and, more broadly, on the environmental resistome
(Toutain and Bousquet-Melou, 2013; Toutain et al., 2015).
The rationale for and urgency of this proposal is that (i) the
worldwide consumption of AMDs to treat or prevent health
conditions in food-producing animals will ineluctably increase
over the coming decades (Van Boeckel et al., 2015) (ii) the so-
called prudent use of AMDs will not stem the rise in AMR of
animal pathogens and commensals and its subsequent impact on
the human resistome.
New, eco-friendly, veterinary AMDs can readily be developed
from currently used drug classes to provide credible alternative
agents. The viability of this approach is enhanced by the fact
that alternatives to AMD use are either not available or not
implementable as reviewed by Cheng et al. (2014). The green
antibiotic principle is in line with the so-called eco-evo concepts
that consider AMR in the broad light of evolution and ecology,
rather than that of narrow clinical practices relating to infections
(Baquero et al., 2011). In this review, we first consider the animal
and human commensal microbiota as comprising a “turnstile” for
exchanges between the two resistomes, and then outline the ideal
properties of a green antibiotic. Finally, the regulatory aspects
that should be addressed to facilitate the promotion of green
antibiotics will be discussed.
ONE WORLD, ONE HEALTH AND “ONE
RESISTOME”
In adhering to the principle of One world, One health (i.e.,
acknowledging the interconnections between animal and human
health and the environment) the priorities for veterinary
AMD therapy are dictated by public health rather than
animal health issues. The tonnage consumption of AMDs in
veterinary medicine exceeds that of human medicine (World
Health Organisation, 2012), and it is recognized that veterinary
medicine contributes to the emergence and spread of AMR
in humans. Available epidemiological methods alone are often
insufficient to accurately describe the relationships between
agricultural AMD use and resistance (Singer and Williams-
Nguyen, 2014). Therefore, the veterinary contribution to human
AMR remains uncertain, with opinion ranging from globally
negligible (Phillips et al., 2004) or irrelevant [an example is
resistance to fluoroquinolones in Escherichia coli and non-
typhoidal Salmonella zoonosis (de Jong et al., 2012)], to one of
a major concern (Collignon et al., 2013). Despite this division
of opinion, it is clear that AMD uses in livestock play some
role in the emergence, amplification, persistence and transfer of
resistance determinants to all ecosystems (Marshall and Levy,
2011) and the main justification in promoting the concept of
green antibiotics is to minimize the veterinary contribution to the
enrichment of human and environmental resistomes.
WHAT TYPES OF ANTIMICROBIAL
DRUG RESISTANCE DOES VETERINARY
MEDICINE FACE AND WHICH RAISE
PUBLIC HEALTH ISSUES?
Veterinary medicine faces AMR of three types: AMR for specific
animal pathogens; AMR for zoonotic pathogens; and AMR of the
commensal bacteria harbored by animals (Figure 1).
Antimicrobial resistance of specific animal pathogens raises
veterinary problems in terms of efficacy but, for two reasons,
has no direct impact on human medicine: (i) these pathogens
(resistant or not) are not in most instances zoonotic and (ii) more
importantly, the size of these pathogenic microbiota is negligible,
when compared to the size of the commensal microbiota that are
collaterally exposed during AMD treatment (see later).
Antimicrobial resistance of foodborne zoonotic pathogens,
causing enteritis and diarrhea, such as Salmonella (Salmonella
typhimurium and S. enteritidis), Campylobacter jejuni (in
poultry), C. coli (in pigs) and some strains of E. coli such as
E. coli O157:H7 are of greater concern. This was the case
for the in ovo administration of ceftiofur, an emblematic
example of AMD misuse in hatcheries, with the aim of
improving the sanitary status of chickens (Dutil et al., 2010).
However, the emergence of AMR in foodborne pathogens is
not the most relevant hazard of veterinary origin for human
medicine. According to a recent EFSA report on human cases
of salmonellosis and campylobacteriosis in the EU (European
Food Safety Authority, 2014b), approximately 200 deaths were
attributable annually to these zoonoses. This number is placed
in perspective by the claimed 25,000 deaths attributed to
AMR annually in the EU (World Health Organisation, 2015).
Similar figures were reported in the USA (Centers for Disease
Control and Prevention, 2013). Moreover, AMR per se is not
responsible for these fatalities, as most zoonotic Salmonella and
Campylobacter of EU foodborne origin are susceptible to the
drugs available to treat these infections (European Food Safety
Authority, 2014a). Furthermore, most cases of salmonellosis and
campylobacteriosis in humans are self-limiting, not requiring
antimicrobial treatment. Moreover, outbreaks of salmonellosis,
at least in the EU, are decreasing; a 30% decline has been
reported over the past 5 years (European Food Safety Authority,
2014b). Therefore, it can be concluded that resistance to
zoonotic pathogens is an individual person medical issue
and not a global ecological and economic hazard for the
future.
The hazards associated with AMR at the level of the animal’s
commensal microbiota, i.e., organisms of the GIT and possibly
of the skin are potentially much more serious ecologically. This
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FIGURE 1 | Classes of bacteria developing resistance under the influence of veterinary AMD usage and consequences for animal, human and public
health. The veterinary use of AMDs is inescapably linked to the risk of emergence of AMR in veterinary targeted pathogens, zoonotic food-borne pathogens and the
animal commensal microbiota. AMR for the targeted pathogen raises animal health issues only, whereas AMR for zoonotic pathogens and bacteria in the
commensal microbiota (principally in the digestive tract) raises public health issues. However, for zoonotic pathogens, the problem, although important, is solely an
individual medical problem. For the animal commensal microbiota, on the other hand, the concern is ecological, collective and worldwide. It is this latter issue that
drives the requirement for new, green AMDs in veterinary medicine.
is because their biomasses greatly exceed those of the specific
or zoonotic pathogens harbored by the same treated animals
(Figure 2). It is likely that the amplification of pre-existing or
emerging genes of resistance displays some proportionality with
both the size and genetic richness of each category of microbiota,
whether pathogenic or not, harbored by treated animals. The
commensal microbiota bacteria are not pathogenic but they
ineluctably harbor, even before any antimicrobial treatment, a
range of genes of resistance (the so-called resistome). The use of
veterinary AMDs can promote the selection and amplification of
the GIT resistant genes, which may then be transmitted directly
(principally by the food chain) or indirectly (via the environment)
to man. After gaining access to the human GIT microbiota,
these “Trojan horse” bacteria may transmit their resistance
genes to the human commensal bacteria by horizontal transfer;
these genes of resistance may then be acquired by human-
specific pathogens (Angulo et al., 2004) or by opportunistic
bacteria such as Enterococcus spp. responsible for nosocomial
infections.
To assess this collateral risk of AMD use in veterinary
medicine, AMR in commensal bacteria is being monitored
in indicator organisms of food-producing animals, E. coli for
the Gram negative microbiota and Enterococcus (Enterococcus
faecium and E. faecalis) for the Gram-positive commensal
intestinal microbiota (European Food Safety Authority, 2013).
For commensal E.coli, the link between the quantities of the
different classes of AMDs administered to food-producing
animals in EU and the prevalence of resistance in isolates
from cattle, pigs, and poultry was demonstrated (Chantziaras
et al., 2014). These epidemiological data drive the proposal
that both human and veterinary medicine will benefit from the
development of green AMDs by limiting the impact of AMD
treatment on the animal commensal resistome and thence on that
of humans.
SHORTCOMINGS OF THE PARADIGM OF
PRUDENT USE OF AMDs IN
VETERINARY MEDICINE
Many recommendations have been made on the prudent use
of AMDs in livestock, to mitigate the emergence of AMR by
promoting their sustainable use in animals. The most effective
decisions, a priori, are those that enforce drastic reductions in
the overall consumption of AMDs. However, the reduction of
such use has, in some cases, produced unexpected results. For
tetracycline resistance in fecal coliforms isolated from swine, the
decrease was less than 50%, after the use of all classes of AMD had
been discontinued for 126 months (Langlois et al., 1983). In the
USA, the decision in 2005 to ban enrofloxacin for metaphylactic
use in poultry was not followed by the expected decrease in
AMR for Campylobacter. Indeed, by 2010 the prevalence of
ciprofloxacin-resistant C. jejuni remained >20% for poultry and
human clinical isolates (Food and Drug Administration, 2012).
Among the factors explaining the limited efficiency of a ban or
of voluntary restriction of AMD use, the most challenging, is of
ecological origin. When a wild-susceptible bacterial population
has been replaced in the environment by an antimicrobial-
resistant population, having no or low fitness costs associated
with the mechanism of resistance, the emergent resistant
population can become very stable in its ecosystem (Andersson
and Hughes, 2010). Indeed, it was shown for Campylobacter
in the USA that some mutations conveying resistance to
ciprofloxacin might even provide a fitness advantage (Luo et al.,
2005; Zhang et al., 2006). The general conclusion from bans
and moratoriums is that retrospective measures will be less
effective than tackling the factors leading to AMR emergence and
dissemination in the first instance.
When the use of AMDs in animals is justified by welfare
and economic considerations, veterinary prescribers have been
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FIGURE 2 | Bacterial load exposed to AMDs during and after treatment, and the duration of exposure. One important category of bovine respiratory
disease is pasteurellosis. Roof (2011) estimated the pathogen load for the entire lung to be 2 × 107–2 × 108 colony forming units (CFU) for Pasteurella multocida
and 9 × 106–9 × 108 CFU for Mannheimia haemolytica. Therefore, the estimated pathogen biomass in the lung of an infected cow does not exceed a few mg in
toto, whereas the bacterial mass in the animal’s commensal GIT microbiota amounts to several kg. The duration of exposure of the target pathogen can be nil
(prophylactic use) or very short (with rapid pathogen eradication during metaphylaxis). In contrast, the duration of intestinal microbiota exposure will never be less
than the duration of treatment plus the delay in fully clearing the AMD, together with any newly formed resistant bacteria from the intestinal microbiota, i.e., several
weeks (Hansen et al., 2002). The GIT microbiota are continually eliminated at a high rate into the environment, often into an aqueous matrix, thereby allowing further
dissemination of the excreted and potentially resistant bacteria. Furthermore, this process will favor horizontal exchanges of resistance factors between organisms
within this vast ecosystem. In consequence, this pathway of bacterial elimination (together with their genes) via the excreta is by far the largest connection between
animal and human resistomes.
encouraged to follow guidelines to ensure their so-called
“prudent” use. Unfortunately, many recommendations have
simply been transposed from human to veterinary medicine,
without recognition that they may be inefficient and even
counterproductive in respect of public health (Figure 3). As
indicated above, the microbiota of public health interest are
the animal GIT microbiota and ultimately the microbiota in
the environment, rather than the target pathogen. For example,
there is no certainty that the priority given to using older AMD
classes, such as tetracyclines, qualified by EMA as category 1
(lower risk) drugs (European Medicine Agency, 2014) will be
less detrimental to the human and environmental resistomes
than, for example, a third generation cephalosporin, specifically
developed to have minimal impact on the GIT microbiota and
which is rapidly degraded in the environment. Indeed, the poor
oral bioavailability of tetracyclines in food-producing animals
is a factor leading to extensive animal GIT and environmental
exposures. Resistance to tetracyclines is commonly associated
with multi-drug resistant bacteria, able to co-select genes
conferring resistance to highly critical AMDs for man (Herrick
et al., 2014), despite the fact that these AMDs are not marketed or
legally restricted in use for food-producing animals.
THE DISCOVERY AND
IMPLEMENTATION OF ALTERNATIVES
TO AMDs
Superficially attractive alternatives to AMDs include vaccines,
antibodies to specific pathogens, immunomodulatory agents,
bacteriophages, antimicrobial peptides and pro-, pre-, or
symbiotic products. An example is the marked reduction
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FIGURE 3 | Priority and stewardship for human and veterinary
medicine and the paradigm of prudent use of AMDs. The paradigm of
prudent use of AMDs in animals can be insufficient and even
counter-productive. This is because such recommendations fail to recognize
that the main sources of the resistance determinants, which are amplified by
veterinary AMD usage, are derived not from the pathogenic microbiota but
from the commensal GIT microbiota. An appropriate stewardship regarding
the target pathogen (the priority for human medicine) can actually increase the
public health issues when directly extrapolated to veterinary medicine. For
example, one recommendation, for the prudent use of AMDs in human and
animal medicine, fully justified from both animal and human health
perspectives, is the possible increase of dosage regimens for older drugs to
comply with current PK/PD concepts. However, this may be detrimental from
the perspective public health. A second example of a questionable
recommendation is the compulsory recourse to Antimicrobial Susceptibility
Testing for AMDs classified as critical for human use, when, in most instances,
there are no specific corresponding veterinary breakpoints. Another issue is
the marketing of inexpensive generic products in veterinary medicine.
Although these have important uses in disease control, there is the possibility
that they might be used clinically when (more costly) hygienic, husbandry and
disease containment options would be more appropriate [for details see
(Toutain and Bousquet-Melou, 2013)]. An a priori sound recommendation is to
give preference to local rather than systemic AMD administration, as in the
treatment of clinical mastitis or at drying off in dairy cattle. In fact this may be
counterproductive as it does not allow for the fact that the waste and
unsaleable milk (containing a higher residual amount of AMD than that
associated with systemic treatment), is commonly used to feed calves and
may be responsible for the emergence of resistance in their GIT microbiota
(Brunton et al., 2012; Duse et al., 2013).
of AMD consumption in Norway, following the marketing
of an efficacious vaccine for the prevention of furunculosis
(Midtlyng et al., 2011). Similarly, the use of a vaccine
to prevent diarrhea due to Lawsonia intracellularis in pigs
led to the reduction of AMD consumption in Danish pigs
(DANMAP, 2014). However, for biological, technical, economic,
medical and regulatory reasons, vaccines (like many putative
alternatives to antibiotics) may be difficult to develop in
veterinary medicine [reviewed by (Cheng et al., 2014)]. Moreover,
some AMD alternatives can have negative consequences for
public health, including the unexpected promotion of AMR.
For example, food supplementation with trace elements,
such as Zn and Cu, proposed as alternatives to AMDs
to control colibacillosis in pigs (Fairbrother et al., 2005;
Hojberg et al., 2005) increased the proportion of multi-
resistant E. coli in vivo in the enteral microbiome of pigs
(Bednorz et al., 2013) and also increased resistance to
methicillin in staphylococci (reviewed by Yazdankhah et al.,
2014).
WHICH ANIMAL BACTERIAL
ECOSYSTEMS PROMOTE AMR OF
HUMAN HEALTH RELEVANCE?
The animal bacterial ecosystems possibly exposed to AMDs
during treatment, and able to promote AMR of human health
relevance, must be identified. In this review, three types of
microbial ecosystems are considered, based on the two main
hazard factors for the emergence and spread of resistance. The
factors are their biomass and the link of each system with the
environment: (i) large, open bacterial ecosystems, such as the
GIT and skin microbiota; (ii) small, open ecosystems, such as
the respiratory tract; and (iii) small, closed ecosystems, such as
the udder in cattle. The healthy udder is a closed system with
no resident flora and is unable to foster a significant source
of AMR during systemic AMD administration. The lung is
an open system with no relevant resident microbiota and the
bacterial biomass in the lung exposed to AMD during a lung
infection is very small, not exceeding a few mg (Figure 2). In
contrast, considering the estimated total numbers of prokaryotes
in the GIT of some domestic species (Whitman et al., 1998)
and assuming an average weight of 1 pg per prokaryote cell,
the bacterial biomasses in the digestive tract of a typical pig,
cow, chicken, and man are approximately 500, 3,000, 0.2,
and 70 g, respectively. Thus GIT biomass is several orders of
magnitude greater than that of the target lung pathogens. In
addition, the GIT microbiota contain a large genetic diversity,
including many resistance genes that can be amplified, and
they have a long residence time in the GIT, favoring exchanges
of resistance genes. There is, moreover, a regular large scale
release of this bacterial population into the environment, thereby
potentially impacting on the emergence and/or selection of
AMR.
Sludge and manure are waste products exposed to AMDs
or their active metabolites, not only during antimicrobial
treatments but also long after its completion; the bacterial
biomass exposed to AMDs is expressed in tons, not mg as
for the target pathogen or kg for the commensal microbiota
(Figure 3). Indeed, in cattle feces production rates are 12 kg/day
for calves, 26 kg/day for beef and 62 kg/day for milk cows.
In pigs, the daily production of manure is 1 to 4 kg and
for egg-laying poultry it is approximately 100 g (Hofmann,
2008). In consequence, the risk, when treating a pulmonary
infection in domestic species, is not due to AMD exposure of
the targeted pathogens but to the unwanted exposure of the
intestinal microbiota to the administered drug and beyond, to
the persistency of its biological effects in soil and water bacterial
populations (van den Bogaard and Stobberingh, 2000; O’Brien,
2002).
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WHY VETERINARY ANTIMICROBIAL
TREATMENTS ARE ABLE TO ALTER THE
RESISTOME OF THE ANIMAL GIT
MICROBIOTA
In food-producing animals, the most convenient route
of AMD administration is orally (Figure 4); this allows
collective treatment at the herd or flock level for prophylaxis
or metaphylaxis. Metaphylaxis also termed control in US
correspond to the collective treatment of all animal of a group
when only a given percentage of subjects of this group display
the first signs of infection while prophylaxis is the administration
of antibiotic when only a risk factor is present (weaning in piglet,
transportation in calves, drying off in dairy cattle. . .).
The classes of oral AMDS most commonly used in food-
producing animals are tetracyclines, β-lactams and
sulphonamides. Tetracyclines (tetracycline, chlortetracycline,
oxytetracycline and doxycycline) have very low oral bio-
availability in pigs, with values typically between 5 and 15%
(Pijpers et al., 1991; Nielsen and Gyrd-Hansen, 1996). In poultry,
bioavailability is even lower, generally not exceeding 5% (Pollet
et al., 1983). The unabsorbed drug fraction (85–95%) transits
into the distal sections of the GIT (caecum, colon) exposing the
body’s densest bacterial population for a duration that commonly
exceeds treatment duration (Hansen et al., 2002). Thereafter, the
unabsorbed fraction is excreted in feces into the environment
as microbiologically active compounds. The oral bioavailability
for ampicillin in pigs is also very low (10%), accounting for an
altered microflora within 24 h after a single dose, and requiring
several weeks before return to the control microbiota organisms
(Bibbal et al., 2007).
Exposure of GIT microorganisms may also be high after
systemic administration (intramuscular, subcutaneous injection)
as most drugs used in veterinary medicine are to varying degrees
eliminated by the digestive tract via intestinal efflux pumps as
P-glycoprotein for quinolones (Alvarez et al., 2008). It may
be noted that large fractions of the Campylobacter C. jejuni
and C. coli populations adhere directly to the intestinal brush
border (Naess et al., 1988) precisely where these efflux pumps
are located. The consequence is a local high concentration in
the mucosa-associated mucus layer, reported to be a site for
the development of resistance to fluoroquinolones (Stamey and
Bragonje, 1976).
After systemic administration most veterinary AMDs
can attain intestinal concentrations capable of inhibiting
intestinal bacteria and selecting resistant organisms. For
example, it was shown that after intramuscular administration
of ampicillin in pigs (20 mg/kg for 7 days), excretion of
the Bla-TEM gene was immediately increased after the first
dose (Bibbal et al., 2007). Quinolones are also extensively
excreted into the GIT. After intravenous administration
of danofloxacin in healthy pigs, high concentrations were
present in all parts of the intestinal tract, resulting in AUC
content-to-plasma ratios between 52·4:1 and 99·4:1 (Lindecrona
et al., 2000). Foster et al. (2016), using ultrafiltration devices
implanted in the GIT lumen, measured free enrofloxacin
(active fraction) concentrations. The AUC intestinal fluid-to-
plasma ratios were 1.6:1 and 2.5:1 in the ileum and colon,
respectively. The intestinal concentrations were shown to be
bactericidal for S. enterica and able to significantly inhibit
E. faecalis.
Cephalosporins are more hydrophilic than fluoroquinolones
and the lower intestinal exposure expected after parenteral
administration has been verified after a subcutaneous ceftiofur
administration. The penetration ratios were 0.39:1 and 0.25:1 for
the ileum and colon, respectively, suggesting that ceftiofur is less
extensively intestinally excreted than fluoroquinolones(Foster
et al., 2016).
Macrolides are also excreted into the GIT but their local
action should take into account the pH dependency of their
antimicrobial activity. The pH in the colon contents of growing
beef cattle and pigs is usually less than 7.0, which is likely
to decrease macrolide potency. This might explain the lack
of antimicrobial activity of tildipirosin in the GIT, after
administration to beef cattle and pigs, for against foodborne
pathogens and commensal bacteria (Rose et al., 2016).
ELIMINATION OF AMDs IN THE
ENVIRONMENT AND IMPACT ON
ENVIRONMENTAL MICROBIOTA
It is acknowledged that the selection of AMD-resistant bacteria
in the environment could jeopardize human health (Ashbolt
et al., 2013; Wellington et al., 2013). Many of the known
resistance factors of clinical concern have been recruited from
non-pathogenic environmental bacteria (Bonomo and Szabo,
2006).
Sources of the AMDs contaminating the environment include
food-producing animals excreting active compounds in feces
and/or urine with the potential for exerting selective pressure
on the microbiota in waste, sludge and manure (Heuer et al.,
2011) and thereafter in the matrices of the environment (water,
soil.) [reviewed by (Sarmah et al., 2006)]. In addition, several
AMDs remain stable in the environment for several weeks or even
months (Thiele-Bruhn, 2003).
The environmental pathways of AMR exchanges between
animals and humans reveal new opportunities to mitigate the
proliferation of resistant bacteria by appropriate management of
human and agricultural waste for the currently used AMDs and
highlight advantages of green AMDs which are either excreted as
inactive metabolites or rapidly inactivated in the environment.
PATHWAYS FOR TRANSMISSION
BETWEEN ANIMAL AND HUMAN
RESISTOMES
Several pathways allow exchanges between the animal and human
microbiomes. Those most relevant for food-producing animals
are directly from animal-to-man via the food chain (Aidara-Kane
et al., 2013) or indirectly via the multiple intricate pathways of the
environment [reviewed by (Ashbolt et al., 2013)].
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FIGURE 4 | Impact of AMD administration on the Gastrointestinal (GIT) microbiota after oral and parenteral administration. (A) After oral AMD
administration, the distal intestinal microbiota (comprising zoonotic pathogens and the commensal flora) is exposed to the unabsorbed drug fraction in the proximal
segment of the digestive tract (1-F%, where F = bioavailability). Potentially, this can lead to local selective pressure, thereby increasing the density of the resistant
bacteria and resistance genes. This load of enriched resistant bacteria and resistance genes is then released into the environment via fecal excretion. These
organisms and genes can reach humans by several pathways and thereby ultimately gain access to the human GIT microbiota. The principal pathway is via the food
chain. (B) After systemic AMD administration most drugs used in veterinary medicine are eliminated, to varying degrees but often extensively, in the digestive tract,
either by biliary secretion or by intestinal clearance as a consequence of efflux pumps in the GIT wall. Intestinal drug concentrations capable of selecting for resistant
organisms, with consequential detrimental effects, may occur, as for the oral administration route. In addition, the impact of AMDs on the animal GIT microbiota is
not limited to the easily cultivable aerobic fraction, which accounts for only 1–2% of the total microbiota (typically Escherichia coli and E. faeciens which are
considered as sentinel bacteria). AMDs can also negatively impact on the much larger anaerobic population [reviewed by (Holman and Chenier, 2015)].
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FIGURE 5 | Animal and human commensal microbiota illustrating the passage of resistance genes from animals to humans. The acquisition in healthy
subjects, either of resistance genes or resistant bacteria from food-producing animals, involves the pivotal role of the human commensal GIT microbiota. This can be
regarded as a sieving filter, able first to retain and then amplify genes of resistance derived from the food chain or the environment. These persisting genes may
subsequently be transmitted, possibly after a long delay, to specific human pathogens.
Scenarios for the transmission of veterinary AMR factors
to humans are consistent with the hypothesis of a pivotal
role of the human commensal microbiota in the natural
history of human infections (van der Waaij and Nord, 2000;
Andremont, 2003; Andremont et al., 2011; Figure 5). There
are two major avenues for the emergence and spread of
AMR in pathogenic bacteria in humans: the first is by
direct selection of resistant mutants within the population
of pathogenic organisms at the site of infection, followed by
dissemination to a new patient by direct exposure, as occurs in
confined hospital environments (epidemic pathway); the second
is indirect, involving an initial selection of resistant bacteria
in the commensal microbiota through horizontal transfer of
resistance genes from non-pathogenic to pathogenic species
and subsequent transfer of pathogenic bacteria, with a possible
delayed effect on the host. Currently, the intestinal microbiota
play a central role in the amplification, dissemination, and
circulation of AMR between humans. This arises from diffusion
into the community of enterobacteria producing extended
spectrum β-lactamases (ESBL), predominantly of CTX-M type,
produced by E. coli, which is ubiquitous in commensal
microbiota. Thus, the human digestive tract can be viewed
as an open door to AMR determinants from various external
sources including food animals. Any subject (patient or not)
is likely to be permanently exposed to resistance determinants
(through the food chain, from the terrestrial and aquatic
environments. . .) depending on the individual’s risk factors.
These harmless bacteria and their resistance determinants are
ingested and expose the GIT commensal microbiota, which
can be viewed as a retention filter able to construct, for
each individual, a personal pool of resistance genes, with
the potential to subsequently undergo horizontal transfer to
pathogens.
Transfer of resistance genes between E. coli residing in the
human intestine was experimentally demonstrated in human
volunteers (Trobos et al., 2009). Furthermore, the in vivo transfer
of resistance genes from E. faecalis isolated from food of animal
origin to a human isolate was demonstrated using a mouse model
(Sparo et al., 2012). Finally, it was concluded from a mathematical
model, evaluating factors affecting the prevalence of human
commensal resistant bacteria causing opportunistic infections
(e.g., enterococci), that the appearance of AMR bacteria in
humans is hastened by the use of AMDs in agriculture (Smith
et al., 2002).
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THE LIMITATIONS OF
PHARMACODYNAMIC SELECTIVITY
AND THE REQUIREMENT FOR
PHARMACOKINETIC SELECTIVITY
For AMDs, selectivity as generally understood, implies narrow
spectrum of activity; for the prudent use of veterinary
AMDs, narrow spectrum are preferred to broad spectrum
agents (European Medicines Agency, 2015b). However,
this recommendation relates to the target pathogen and
pharmacodynamic selectivity alone cannot resolve public
health considerations, because of the range of bacterial species,
both Gram-positive and Gram-negative, in the commensal
microbiota. For a sustainable veterinary AMD usage, the
selectivity required is primarily pharmacokinetic and not
pharmacodynamic. Thus, drug distribution in the body should
ideally be restricted to the biophase (site of action) and,
as a minimal requirement, excluded from the commensal
GIT microbiota. The latter objective can be achieved either
by selecting drugs not eliminated in the GIT or, if a drug
is nevertheless present in active form in the distal GIT, by
suppressing its activity through physical trapping or by favoring
its local degradation into inactive compounds. An example is use
of β-lactamases for β-lactam compounds [reviewed by (van der
Waaij and Nord, 2000)].
Almost all currently used veterinary AMDs are eliminated
into the GIT. For orally administered AMD, the principal
factor is low bioavailability (see above) whilst for systemic
administration the main factor is high biliary and/or intestinal
clearance, both of which are associated with high drug
lipophilicity. The physico-chemical properties of AMDs used in
humans differ from those of other therapeutic classes. Human
AMDs have a higher MW (371 ± 161 Da) and a lower
lipophilicity (Calculated log octanol/water Partition coefficient,
Clog P of −0.18 ± 1.88) than drugs of other classes. In
addition, protein binding is relatively low for most AMDs and
urinary excretion ratio relatively high (Sakaeda et al., 2001).
In contrast, for AMDs used in food-producing animals, the
position differs. For example, the 10 AMDs routinely used
to treat bovine respiratory disease (O’Connor et al., 2013)
have a higher MW (557 ± 220) and are more lipophilic
(Clog P 1.8 ± 2.18) than those used in human medicine
(Table 1).
Lipophilic drugs are selected for veterinary use for two
reasons: first, the requirement for long duration of action,
the terminal half-life being positively correlated to the degree
of lipophilicity [the coefficient of determination (R2) for the
10 most used AMDs in cattle R2 = 0.37] (Table 1); and
second, the need to develop more potent AMDs. The potency
of quinolones in humans for S. aureus and E. coli correlates
with lipophilicity (Clog P; Figure 6). Similarly, it would be
valuable to assess the relationship between effectiveness of
AMD (especially of quinolones and cephalosporins) to alter
the GIT microbiota and their lipophilicity, because not all
drugs of a given class are equivalent. The potential for
developing more eco-friendly drugs recognizes that the most
potent lipophilic AMDs are also likely the least selective
in terms of tissue distribution. In fact, eco-friendly AMDs,
such as ceftaroline (Panagiotidis et al., 2010) telavancin,
dalbavancin (Nord and Edlund, 1990; van der Waaij and
Nord, 2000; Edlung and Nord, 2003; Rashid et al., 2011,
2012) already exist in human medicine. This supports the
feasibility of developing specific green AMDs in veterinary
medicine. For this objective, it is necessary to recognize that
a less potent drug is not synonymous with reduced clinical
efficacy; it simply implies (other factors being equal in terms
of pharmacological activity and clearance) a higher dosage
regimen.
IDEAL PHARMACOKINETIC AND
PHARMACODYNAMIC PROFILES TO
MINIMIZE PUBLIC HEALTH ISSUES
The ideal AMD for food-producing animals should possess
several pharmacokinetic and pharmacodynamic characteristics
TABLE 1 | Relationship between lipophilicity and pharmacokinetic parameters for the 10 most used antimicrobial in cattle.
Antimicrobials Classes Molecular weight XLogP3-AA Vss (L/kg) Clearance (mL/kg/min) Half-life (h)
Ceftiofur Cephalosporins 523.56 0.20 0.30 0.55 7.00
Danofloxacin Fluoroquinolones 357.38 −0.30 2.48 8.30 4.01
Enrofloxacin Fluoroquinolones 359.39 −0.20 1.80 3.20 6.60
Florfenicol Amphenicols 358.21 0.80 0.77 3.75 2.65
Gamithromycin Macrolides 777.03 4.90 24.90 11.86 44.90
Oxytetracycline Tetracyclines 460.43 −1.60 0.79 1.88 5.66
Tildipirosin Macrolides 734.01 4.30 21.80 2.40 238.00
Tilmicosin Macrolides 869.13 3.60 28.20 11.40 28.00
Trimethoprim Diaminopyrimidine 290.32 0.90 1.50 28.33 1.20
Tulathromycin Macrolides 806.08 3.80 11.1 3.01 65
Mean 556.89 1.80 10.37 8.24 40.30
XlogP3 is the computed Octanol-Water Partition Coefficients (log P; Cheng et al., 2007) as given by PubMed ComPound; Vss: volume of distribution in steady-state
condition. The 10 AMDs routinely used to treat bovine respiratory disease were listed by (O’Connor et al., 2013) they have a higher MW (557 ± 220) and are more
lipophilic (log P = 1.8 ± 2.18) than those used in human medicine. The terminal half-life is positively correlated to the degree of lipophilicity with a coefficient of
determination (R2) between lipophilicity and duration of half-of 0.37.
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FIGURE 6 | Relationship between lipophilicity and potency of
fluoroquinolones. Potency of a series of fluoroquinolones was measured as
the MIC against Staphylococcus aureus (A) and E. coli (B); MIC data are from
Takenouchi et al. (1996) and Clog P was obtained from PubChem Compound.
As lipophilicity (and hydrophobicity) increase, so potency increases also.
to ensure practicability for use under field conditions,
whilst having no detrimental impact on the GIT microbiota
(Figure 7).
High Oral Bioavailability
For oral dosing, a high bioavailability is required for two reasons:
first, to minimize the unwanted impact on the GIT microbiota
by the unabsorbed fraction; and secondly, because a high
bioavailability is almost always associated with a lower between-
animal variability (Toutain and Bousquet-Mélou, 2004a). Due
to inter-animal variability, drug companies are constrained to
selection of a high population dose to ensure efficacy for a high
proportion of treated animals (usually the target attainment rate
is 90%).
Development of AMDs with high oral bioavailability
presents a significant challenge, as illustrated by the low oral
bioavailability of currently used drugs in food producing
animals. Studies comparing fasted and fed animals or before
and after weaning demonstrated that feed (e.g., milk vs. hay)
could have a large negative impact on oral bioavailability.
This is likely attributable to the adsorption capacity of
feed and especially of cellulose, a major constituent of
animal feed (Ratz et al., 1995). Therefore, a green orally
administered AMD should interact minimally with feed
constituents.
For the unbound feed fraction, the ‘rule of five,’ also known
as the Lipinski rule (Lipinski, 2000) provides guidance on
factors controlling oral drug absorption; Lipinski’s ‘rule of
five,’ is based on five descriptors of drug physico-chemical
properties. The most important is lipophilicity, as quantified
by the LogP (or Clog P). The degree of lipophilicity influences
drug solubility and ability to permeate both intestinal epithelial
cells and bacterial cell walls and membranes. Compounds
that are too hydrophilic (having negative LogP) do not cross
intestinal membranes and the ideal LogP is of the order
of 2–3. Conversely, compounds with an a priori appropriate
lipophilicity for oral absorption may be too lipophilic to penetrate
bacteria. This is because drug penetration through the two
bacterial membranes depends: first, on the balance between
a hydrophilicity requirement (typically a negative LogP) to
facilitate passage through water channels (aquaporins) tunneling
outer bacterial membranes (especially in Gram-negative bacteria)
and; second, a lipophilicity requirement to penetrate the
inner lipid rich membrane, when the molecular target is
intracellular, e.g., ribosomal bacterial enzymes (macrolides,
tetracyclines. . .).
When the site of action is located between the two
membranes, as for β-lactams or colistin-like drugs, the
requirement is for more hydrophilic compounds. There is
a trade-off between lipophilicity for optimal oral bioavailability
and hydrophilicity for optimal bacterial penetration; most
AMDs in veterinary use do not conform to the stipulations
of the rule of five (Lipinski et al., 2001). The development
of green AMDs should take into account that less lipophilic
(more hydrophilic) compounds are required than other
drug classes. To resolve this dual requirement, a pro-drug
approach is an attractive option; a relatively lipophilic and well
absorbed pro-drug, followed by first-pass hepatic metabolism
to generate an active, more hydrophilic, metabolite. This
strategy was deployed effectively for pro-drugs of ampicillin
(LogP = 0.57) such as bacampicillin (LogP = 2.04) and
pivampicillin (LogP= 2.4).
Development of Products (Substances or
Formulations) Ensuring Persistency of
Effective Plasma Concentrations
In ruminating cattle and some swine production systems,
intramuscular, and subcutaneous administration routes are
extensively used. Formulations with high systemic bioavailability
are readily achieved and there is no direct exposure of the
GIT microbiota, as with the oral route. However, parenteral
administration must allow for an appropriate duration of
activity. In contrast to oral dosing, the requirement is for
long-acting products to provide bacteriological cure with single
dose administration. Such products avoid fluctuating plasma
and biophase drug concentrations and are desirable also from
economic and animal welfare perspectives.
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FIGURE 7 | Pharmacokinetic profile of the ideal veterinary green AMD. The left panel indicates that the green AMD should not have a large volume of
distribution. However, as volume of distribution is, with plasma clearance, one of two determinants of terminal half-life, an AMD with low volume of distribution will
usually have too short a half-life. This is not a significant issue for the oral route, as an AMD with a short half-life can be administered virtually continually in feed or
drinking water, in effect providing an oral infusion. In contrast, this is a major challenge for parenteral routes and development of slow release formulations (especially
for AMDs exerting a time-dependent killing action) is necessary to ensure a long terminal half-life (flip-flop pharmacokinetics), thereby allowing both practicable and
efficacious therapy with single dose administration. The middle panel indicates that a green AMD cannot have either intestinal or biliary clearance as a mechanism of
elimination to ensure that there is no negative impact on the animal GIT microbiota. Clearance by hepatic metabolism is ideal, provided the metabolites are inactive.
Alternatively, a high renal clearance is acceptable, provided the eliminated active drug is rapidly degraded in the environment or immobilized by physical sorption
(right panel).
For cattle bronchopneumonia therapy, the ideal activity
duration is typically at least 5 days. Persistence of action
can be achieved with several strategies, which have differing
consequences in terms of bacteriological selectivity. One option
is to develop a drug substance with a long intrinsic elimination
half-life, as for most macrolides used in food-producing animals.
Half-life is a hybrid parameter controlled by plasma clearance
and drug distribution in peripheral compartments. Therefore,
a long half-life can be obtained either by selecting compounds
with a low clearance or, alternatively, by selecting those with a
large volume of distribution. These strategies are not equivalent
in terms of pharmacokinetic selectivity. Thus, AMDs with a
large volume of distribution cannot be selective, because they
are extensively distributed outside the extracellular water space,
while most pathogens of veterinary interest are located in
this space. Moreover, a large distribution volume is generally
associated with high lipophilicity (Yusof and Segall, 2013) and
such drugs are excreted in the GIT, with possible unwanted effects
on the GIT microbiota. Alternatively, a long half-life can be
obtained if the drug has a low plasma clearance. It is plasma
clearance, not volume of distribution, which controls steady-
state plasma drug concentrations, and hence concentration in the
biophase (Toutain and Bousquet-Mélou, 2004b). In summary,
the optimal strategy in developing a long-acting substance with
the required pharmacokinetic selectivity (located primarily in the
extracellular space) is to select candidates with low clearance
rather than a large volume of distribution. The likelihood
of achieving a low distribution volume at steady state (Vss)
decreases below average if the logP is greater than approximately
one (Yusof and Segall, 2013). Of course, this strategy will
not be suitable for intracellular infections (e.g., caused by
mycoplasmas); these require some lipophilicity to penetrate
intracellularly.
An alternative approach to minimize impact on GIT
microbiota is to develop long-acting formulations, rather
than long-acting compounds, with eco-friendly properties.
The selected compound would have a limited distribution
volume, appropriate clearance and short elimination half-life,
but effective concentrations are ensured through slow but
maintained absorption from the injection site, giving rise
to flip-flop pharmacokinetics (Toutain and Bousquet-Melou,
2004). These new formulations for green AMDs must be
locally well tolerated (non-irritant) and administered as a single
dose.
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Preferential Renal Clearance to Avoid
GIT Microbiota Exposure
The principal routes of AMD elimination are hepatic and renal;
hepatic clearance can comprise both metabolic inactivation and
biliary secretion. Drugs may also be excreted directly into the GIT
lumen by intestinal clearance.
According to (Kusama et al., 2010) the major pathways of
drug clearance can be predicted in silico from knowledge of four
physico-chemical parameters (charge, MW), lipophilicity and
unbound protein fraction in plasma). Each is defined by and can
be deduced from the drug’s molecular structure.
Preferential renal elimination is highly desirable, because
this route is not associated with direct exposure of the GIT
commensal microbiota. Also ideal would be renal elimination
as inactive metabolites, preceded by phase I hepatic metabolism,
to avoid any effect on the environmental microbiome. The
relationship between physico-chemical properties of drugs and
urinary excretion has been documented (Ito et al., 2013). Drugs
that are eliminated unchanged by the kidneys have a small MW,
large unbound fraction and are hydrophilic.
Avoiding Elimination by Biliary or
Intestinal Clearance to Protect the GIT
Microbiome
On the Biopharmaceutics Classification System (Amidon et al.,
1995) drugs are classified as highly or poorly permeable,
according to their rate of transit across intestinal cells. Poorly
permeable drugs generally require an active transport process,
involving efflux transporters, to cross cell membranes efficiently
and many veterinary AMDs and/or their active metabolite(s)
are eliminated into the GIT either by active biliary secretion or
by intestinal clearance. Therefore, potential new drugs should
be screened for a lack of affinity for the biliary and GIT efflux
pumps to ensure no exposure of commensal GIT microbiota.
Lipophilicity and MW are the two most important determinants
for biliary excretion and reliable screening procedures exist
for predicting drug elimination in bile (Rioux et al., 2013).
For intestinal efflux, P-glycoprotein is a well characterized
ABC transporter. It limits the oral bioavailability of poorly
soluble drugs but also extrudes some substances by intestinal
clearance. Fluoroquinolones are substrates for multiple human
ABC transporters (Alvarez et al., 2008) as demonstrated for
enrofloxacin, ciprofloxacin and danofloxacin. P-glycoprotein
substrates tend to have higher lipophilicity and/or larger
MW than non-substrates. In silico models for predicting the
probability that a compound will interact with P-glycoprotein or
analogous transporters are available and could be used to select
candidates for green AMDs (Chen et al., 2012; Montanari and
Ecker, 2015).
DISPOSITION PROPERTIES TO
MINIMIZE ENVIRONMENTAL HAZARD
A green antibiotic should not be eliminated into the environment
as an active substance. If, nevertheless, a potential candidate is
excreted in urine as parent drug or active metabolites, their fate,
and any ongoing activity in the various environmental matrices,
should be determined. The possibility of optimizing degradability
in waste must be considered. Because AMDs generally reach
the environment via water effluent from livestock operations,
hydrolysis is a potentially important degradation pathway.
β-lactams, macrolides, and sulfonamides are three classes
susceptible to hydrolysis (Adams et al., 2013), whereas little or
no degradation was reported for oxytetracycline (Jacobsen and
Berglind, 1988).
Photolysis is also an abiotic transformation process; in
addition, photodegradation can occur at the soil-atmosphere
interface and on the surface of liquid manure. Quinolones and
tetracyclines are susceptible to photodegradation (Huang et al.,
2011) and photodecomposition of AMDs under field conditions
is a desirable property.
Possible interactions of non-degraded AMD fractions with
soil dwelling bacteria should be explored (Subbiah et al., 2011).
This can be accomplished by mixing test antibiotics or their active
metabolites with soil slurries differing in clay content, pH, and
other properties. After mixing, the supernatant can be assayed
with a sensitive E. coli strain that is only inhibited by the freely
available AMD fraction, i.e., the mobile fraction not adsorbed by
soil materials (Subbiah et al., 2011). This type of assay showed
that tetracyclines, neomycin, and ciprofloxacin were not mobile
whereas florfenicol and β-lactams were mostly available in the
liquid phase and therefore able to affect the test bacteria. This
can be also predicted from the organic normalized dissociation
constants (Koc) of candidate compounds. The Koc provides,
although imperfectly, a prediction of how firmly AMDs adsorb
to soil (Tolls, 2001). In addition, sorption coefficients have been
proposed to predict AMD mobility in the environment (Call
et al., 2013).
REGULATORY CONSIDERATIONS
The provision of incentives to develop innovative AMDs requires
a favorable regulatory climate. All regulatory authorities (EMA,
FDA/EPA. . .) must consider the case of green antimicrobials
as alternatives to currently available drugs, as this is essential
to fulfill the main requirement of the One health policy,
namely to be lacking in side-effects for human health and
environment. To promote green AMDs, and to give them
a competitive advantage over conventional AMDs, regulatory
authorities will need to consider the impact of all AMDs (new or
old) on the environmental resistome, before granting a marketing
authorization. Currently, the issue of AMR transmitted by
environmental pathways is not considered in guidelines either for
generic or pioneer products.
A similar situation exists in the USA and it was recently
suggested that EPA “should explore requiring FIFRA (Federal
Insecticide, Fungicide, and Rodenticide Act) registration of
antibiotics used in food animal production. Data requirements for
registration will help focus and support the restricted use that is
important for deterring selection of antibiotic resistance in the food
supply, and in the environment due to farm antibiotic effluents”
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(Metz and Shlaes, 2014). Recently, in the EU, CVMP explicitly
acknowledged “the importance of the environment as a reservoir
for AMR genes” (European Medicines Agency, 2015a) and “the
CVMP will develop a reflection paper to consider the role of AMR
in the environment and the feasibility of addressing this in the
environmental risk assessment for veterinary medicinal products.”
Regulatory authorities will need to obtain and assess data to
facilitate the development of green antibiotics. Examples are:
the provision of robust PK/PD data; confirmation of efficacy in
non-inferiority clinical trials and the submission of data which
clearly demonstrates ecological advantages over conventional
comparators.
According to some economic models, AMR can be
reduced by extending the duration of the patent on pioneer
AMDs, because patents give the owners incentives to protect
the value of their drugs by limiting usage (Horowitz and
Moehring, 2004). The pricing of green antibiotics should
reward industry for costly R&D efforts but this will be difficult
to achieve if the market is dominated by inexpensive older
products (both generic and pioneer products). Prescribing
more expensive green antibiotics, whose advantage is not to
enhance therapeutic outcome but rather to address public health
issues, would be less likely under conditions of farm animal
practice.
An important consideration is the expression of AMD
consumption in terms of mass units. Green AMDs would likely
be less potent than their available counterparts and therefore
would require a higher dosage. Consideration should therefore
be given to adoption of alternative units of measurement, when
reporting antimicrobial consumption data in food-producing
animals. This may be necessary to avoid penalizing green
antibiotics and to ensure a less biased expression system of
AMD consumption (Dewulf et al., 2013). Alternatives have
been adopted in the Netherlands (Taverne et al., 2015) and
Denmark and also in human medicine, where the WHO system
of harmonized Defined Daily Dosages is used.
CONCLUSION
Veterinary AMDs, in the longer term, should be innovative
and expensive, and their marketing strictly regulated, to ensure
minimal public health impact.
The main thesis proposed in this article is that we urgently
need new AMDs in veterinary medicine, because most of
the drugs currently used ineluctably expose the animal GIT
microbiome, through their lack of pharmacokinetic selectivity.
Thereby, they potentially help to enrich the human resistome,
i.e., increase accumulation of AMD resistance genes harbored
by both pathogenic and non-pathogenic human bacteria. The
development of green AMDs is based on the consideration that
AMR of veterinary origin should be viewed as a global ecological
challenge and not as a medical issue and that solutions need to
consider the eco-evo rationale as outlined by (Baquero et al.,
2011). For new and innovative green antibiotics the pivotal
characteristic will be minimal ecological impact. They will possess
appropriate PK/PD selectivity, in that they will be distributed
only or primarily in the biophase where the targeted pathogen
is located. Consequently, they will have no negative impact either
on the commensal GIT microbiota of the treated animal or on
the various matrix/ecosystems of the environment. It should
be possible to achieve these aims by re-evaluating the current
classes of veterinary AMDs and applying the wealth of existing
knowledge of medicinal chemistry to develop more hydrophilic
analogs of these drug. Hence, there should be no requirement
to discover and develop wholly new drug classes, with novel
mechanisms of action that indeed might be challenged on the
ground of new additional AMR risks for human medicine.
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